收购溢价超3倍 爱博医疗押宝运动医学赛道

Core Viewpoint - Aibo Medical, a leading ophthalmic device company, plans to enter the sports medicine sector through the acquisition of 68.31% of Demai Medical for 683 million yuan, which is over three times the net asset value [1][2]. Group 1: Acquisition Details - The acquisition involves a cash payment, with 70%-80% of the transaction price expected to be financed through bank loans, leading to an increase in interest-bearing liabilities on Aibo Medical's consolidated balance sheet [2]. - Demai Medical is a top player in the domestic sports medicine field, with core products including suture anchors and arthroscopic systems, contributing approximately 80% to its revenue [1][3]. Group 2: Financial Implications - As of October 31 of the previous year, Demai Medical's net asset value was 242 million yuan, with an assessed value of 1.074 billion yuan, resulting in an appreciation of 832 million yuan, or 343.29% [3]. - The acquisition is expected to generate approximately 500 million yuan in goodwill for Aibo Medical, which will increase its total goodwill to 691 million yuan post-acquisition [3][4]. Group 3: Strategic Intent - Aibo Medical aims to enhance its performance and shareholder returns by leveraging synergies in R&D, manufacturing, and sales channels with Demai Medical [2]. - The company believes that the transaction price is reasonable as it is lower than the assessed value, taking into account various factors such as core technology and future profitability [3].